BACKGROUND: Menstrual cups have been available for decades, but their use is limited by bulky design and the need for multiple sizes. The Softcup® (Instead, Inc., San Diego, CA) is a simple single-size disposable over-the-counter (OTC) menstrual cup that compresses to tampon shape to facilitate insertion and can be worn during coitus. This report describes preclinical evaluation, clinical testing, and postmarketing monitoring of the Softcup. METHODS: Preclinical testing complied with U.S. Food and Drug Administration (FDA) guidelines and used standard United States Pharmacopoeia methodologies for assessment of potential toxicity. Clinical testing enrolled 406 women in seven U.S. centers. A detailed written questionnaire assessed safety, acceptability, and effectiveness for menstrual collection. Study safety parameters included pelvic examinations, Pap smears, colposcopy, urinalysis, vaginal pH, wet mounts, gram stain, and vaginal microflora cultures. Postmarketing surveillance of over 100 million Softcups has been conducted by the manufacturer and by the FDA Medwatch system. RESULTS: No toxicity or mutagenicity was observed in preclinical evaluations. In clinical testing, after three cycles of cup use, 37% of subjects rated the cup as better than, 29% as worse than, and 34% as equal to pads or tampons. The cup was preferred for comfort, dryness, and less odor. Cups received lower ratings for disposal and convenience. Eighty-one percent of enrolled women were able to insert and remove their first cup using only written instructions. Use difficulties resulting in study discontinuations included cramping (1%), leakage (1%), and improper fit (3%). No safety parameters were adversely affected. No significant health risks were reported during postmarketing surveillance. CONCLUSIONS: These results demonstrate that a single-size vaginal device has no significant health risks and is acceptable to many women without the need for fitting or other medical services.
BACKGROUND:Menstrual cups have been available for decades, but their use is limited by bulky design and the need for multiple sizes. The Softcup® (Instead, Inc., San Diego, CA) is a simple single-size disposable over-the-counter (OTC) menstrual cup that compresses to tampon shape to facilitate insertion and can be worn during coitus. This report describes preclinical evaluation, clinical testing, and postmarketing monitoring of the Softcup. METHODS: Preclinical testing complied with U.S. Food and Drug Administration (FDA) guidelines and used standard United States Pharmacopoeia methodologies for assessment of potential toxicity. Clinical testing enrolled 406 women in seven U.S. centers. A detailed written questionnaire assessed safety, acceptability, and effectiveness for menstrual collection. Study safety parameters included pelvic examinations, Pap smears, colposcopy, urinalysis, vaginal pH, wet mounts, gram stain, and vaginal microflora cultures. Postmarketing surveillance of over 100 million Softcups has been conducted by the manufacturer and by the FDA Medwatch system. RESULTS: No toxicity or mutagenicity was observed in preclinical evaluations. In clinical testing, after three cycles of cup use, 37% of subjects rated the cup as better than, 29% as worse than, and 34% as equal to pads or tampons. The cup was preferred for comfort, dryness, and less odor. Cups received lower ratings for disposal and convenience. Eighty-one percent of enrolled women were able to insert and remove their first cup using only written instructions. Use difficulties resulting in study discontinuations included cramping (1%), leakage (1%), and improper fit (3%). No safety parameters were adversely affected. No significant health risks were reported during postmarketing surveillance. CONCLUSIONS: These results demonstrate that a single-size vaginal device has no significant health risks and is acceptable to many women without the need for fitting or other medical services.
Authors: Ellen Hardy; Karla S de Pádua; Eliana Maria Hebling; Maria José Duarte Osis; Lourens J D Zaneveld Journal: Contraception Date: 2003-05 Impact factor: 3.375
Authors: Shameem Z Jaumdally; Heidi E Jones; Donald R Hoover; Hoyam Gamieldien; Jean-Mari Kriek; Nontokozo Langwenya; Landon Myer; Jo-Ann S Passmore; Catherine S Todd Journal: Am J Reprod Immunol Date: 2017-01-23 Impact factor: 3.886
Authors: Penelope A Phillips-Howard; Elizabeth Nyothach; Feiko O Ter Kuile; Jackton Omoto; Duolao Wang; Clement Zeh; Clayton Onyango; Linda Mason; Kelly T Alexander; Frank O Odhiambo; Alie Eleveld; Aisha Mohammed; Anna M van Eijk; Rhiannon Tudor Edwards; John Vulule; Brian Faragher; Kayla F Laserson Journal: BMJ Open Date: 2016-11-23 Impact factor: 2.692
Authors: Jane Juma; Elizabeth Nyothach; Kayla F Laserson; Clifford Oduor; Lilian Arita; Caroline Ouma; Kelvin Oruko; Jackton Omoto; Linda Mason; Kelly T Alexander; Barry Fields; Clayton Onyango; Penelope A Phillips-Howard Journal: BMJ Open Date: 2017-05-04 Impact factor: 2.692
Authors: Anna Maria van Eijk; Kayla F Laserson; Elizabeth Nyothach; Kelvin Oruko; Jackton Omoto; Linda Mason; Kelly Alexander; Clifford Oduor; Aisha Mohammed; Alie Eleveld; Isaac Ngere; David Obor; John Vulule; Penelope A Phillips-Howard Journal: Reprod Health Date: 2018-08-17 Impact factor: 3.223
Authors: Anna Maria van Eijk; Garazi Zulaika; Madeline Lenchner; Linda Mason; Muthusamy Sivakami; Elizabeth Nyothach; Holger Unger; Kayla Laserson; Penelope A Phillips-Howard Journal: Lancet Public Health Date: 2019-07-16